Laurie D. Stelzer's most recent trade in Sionna Therapeutics Inc. was a trade of 19,959 Non-Qualified Stock Option (right to buy) done . Disclosure was reported to the exchange on June 12, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Sionna Therapeutics Inc. | Laurie D. Stelzer | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2025 | 19,959 | 19,959 | - | - | Non-Qualified Stock Option (right to buy) | |
| PMV Pharmaceuticals Inc | Laurie D. Stelzer | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2025 | 33,500 | 33,500 | - | - | Stock Option (right to buy) | |
| Spyre Therapeutics Inc. | Laurie D. Stelzer | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 May 2025 | 25,000 | 25,000 | - | - | Stock Option (Right to Buy) | |
| PMV Pharmaceuticals Inc | Laurie D. Stelzer | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2024 | 67,500 | 67,500 | - | - | Stock Option (right to buy) | |
| Spyre Therapeutics Inc. | Laurie D. Stelzer | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 May 2024 | 11,323 | 11,323 | - | - | Stock Option (Right to Buy) | |
| Mirati Therapeutics Inc | Laurie D. Stelzer | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 37.00 per share. | 09 Aug 2023 | 22,297 | 102,312 (0%) | 0% | 37 | 824,989 | Common Stock |
| PMV Pharmaceuticals Inc | Laurie D. Stelzer | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2023 | 21,500 | 21,500 | - | - | Stock Option (right to buy) | |
| Mirati Therapeutics Inc | Laurie D. Stelzer | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 37.06 per share. | 02 Jun 2023 | 4,647 | 80,015 (0%) | 0% | 37.1 | 172,218 | Common Stock |
| Mirati Therapeutics Inc | Laurie D. Stelzer | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jan 2023 | 45,456 | 45,456 | - | - | Employee Stock Option (Right to Buy) | |
| Mirati Therapeutics Inc | Laurie D. Stelzer | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jan 2023 | 26,864 | 84,662 (0%) | 0% | 0 | Common Stock | |
| PMV Pharmaceuticals Inc | Laurie D. Stelzer | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2022 | 19,500 | 19,500 | - | - | Stock Option | |
| Mirati Therapeutics Inc | Laurie D. Stelzer | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2022 | 91,164 | 91,164 | - | - | Employee Stock Option (Right to Buy) | |
| Mirati Therapeutics Inc | Laurie D. Stelzer | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2022 | 57,798 | 57,798 (0%) | 0% | 0 | Common Stock | |
| PMV Pharmaceuticals Inc | Laurie D. Stelzer | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2021 | 16,333 | 16,333 | - | - | Stock Option |